Heterocyclic compound
US8912180B2 · kind B2 · utility
10Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2013 |
| Grant date | Dec 16, 2014 |
| Priority date | — |
| Expiry date | Feb 8, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a novel compound which is an agent for treating rejection reactions in various organ transplantations, allergy diseases, autoimmune diseases, and hematologic tumor, and based on a PI3Kδ selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action). The provided compound has a PI3Kδ selective inhibitory action, an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action, including an activation inhibitory action.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.